Meeting News

Secukinumab showed sustained improvements for PsA after 3 years

MADRID — Secukinumab showed sustained improvements in patients with ankylosing spondylitis and in patients with psoriatic arthritis after 3 years, according to findings presented at the EULAR Annual Congress.

Narasimhan
Vas Narasimhan

“These data reconfirm that Cosentyx provides patients with long-lasting relief from the symptoms of psoriatic arthritis, as well as now demonstrating rapid pain relief from psoriatic arthritis,” Vas Narasimhan, global head of drug development and chief medical officer of Novartis, said in a press release. “We are pleased that Cosentyx continues to provide sustained benefits for patients with psoriasis, psoriatic arthritis and ankylosing spondylitis.”

Researchers assessed 397 patients with active psoriatic arthritis who received either 300 mg, 150 mg or 75 mg of secukinumab (Cosentyx, Novartis), or placebo. Investigators found sustained improvements across all clinically important domains of psoriatic arthritis, including ACR70. The exposure incident rates were 1.6 for serious infections, 2.3 for candida infections, 0.5 for inflammatory bowel disease and 1.3 for malignant or unspecified tumors. — by Will Offit

References:

McInnes IB, et al. Abstract #OP0222. Presented at: EULAR Annual Congress; June 14-17, 2017; Madrid.

www.novartis.com

Disclosure: Please see the full abstract for a list of all relevant financial disclosures.

 

MADRID — Secukinumab showed sustained improvements in patients with ankylosing spondylitis and in patients with psoriatic arthritis after 3 years, according to findings presented at the EULAR Annual Congress.

Narasimhan
Vas Narasimhan

“These data reconfirm that Cosentyx provides patients with long-lasting relief from the symptoms of psoriatic arthritis, as well as now demonstrating rapid pain relief from psoriatic arthritis,” Vas Narasimhan, global head of drug development and chief medical officer of Novartis, said in a press release. “We are pleased that Cosentyx continues to provide sustained benefits for patients with psoriasis, psoriatic arthritis and ankylosing spondylitis.”

Researchers assessed 397 patients with active psoriatic arthritis who received either 300 mg, 150 mg or 75 mg of secukinumab (Cosentyx, Novartis), or placebo. Investigators found sustained improvements across all clinically important domains of psoriatic arthritis, including ACR70. The exposure incident rates were 1.6 for serious infections, 2.3 for candida infections, 0.5 for inflammatory bowel disease and 1.3 for malignant or unspecified tumors. — by Will Offit

References:

McInnes IB, et al. Abstract #OP0222. Presented at: EULAR Annual Congress; June 14-17, 2017; Madrid.

www.novartis.com

Disclosure: Please see the full abstract for a list of all relevant financial disclosures.

 

    See more from EULAR Annual Congress